TY - JOUR
T1 - Comparison of p53, Ki-67, and CD44v6 expression between primary and matched metastatic lesions in ovarian cancer
AU - Sakai, Kunihiro
AU - Kaku, Tsunehisa
AU - Kamura, Toshiharu
AU - Kinukawa, Naoko
AU - Amada, Satoshi
AU - Shigematsu, Toshiyuki
AU - Hirakawa, Toshio
AU - Kobayashi, Hiroaki
AU - Ariyoshi, Kazuya
AU - Nakano, Hitoo
PY - 1999/3
Y1 - 1999/3
N2 - Objective. Many studies have demonstrated that clinically evident tumor cells already carry multiple genetic alterations and further accumulation of genetic alteration causes tumor progression which plays a role in metastasis. Therefore, it could be expected that malignant potential in the metastatic site is more aggressive than that in the primary site. Using several immunohistochemical markers (p53, Ki-67, and CD44v6), we investigated an alteration of malignant potential. Methods. We immunohistochemically examined expression of p53, Ki-67, and CD44 in primary and metastatic lesions of ovarian cancer. Fifty-six samples of primary lesions and matched metastatic sites from 56 patients with primary epithelial ovarian cancers were included in this study. Results. In 16 cases (28%), the histological grade of the metastatic lesion increased. This difference was statistically significant (P = 0.0232). In 16 cases (28%), the expression of p53 increased in the metastatic lesions, in 5 pairs from negative to positive, whereas the case decrease in the metastatic lesions was only 1. This difference was statistically significant (P = 0.0046). There was no significant difference in Ki-67 labeling indices and expression of CD44v6 between the primary and matched metastatic lesions. The degree of p53 expression in the metastatic lesions significantly correlated with disease-free survival (P = 0.0482), whereas that in the primary lesions did not. Moreover, high p53 expression in the metastatic lesions significantly correlated with disease-free survival in multivariate analysis. Conclusions. The p53 expression in metastatic lesions may reflect an aggressive biologic behavior in ovarian cancer.
AB - Objective. Many studies have demonstrated that clinically evident tumor cells already carry multiple genetic alterations and further accumulation of genetic alteration causes tumor progression which plays a role in metastasis. Therefore, it could be expected that malignant potential in the metastatic site is more aggressive than that in the primary site. Using several immunohistochemical markers (p53, Ki-67, and CD44v6), we investigated an alteration of malignant potential. Methods. We immunohistochemically examined expression of p53, Ki-67, and CD44 in primary and metastatic lesions of ovarian cancer. Fifty-six samples of primary lesions and matched metastatic sites from 56 patients with primary epithelial ovarian cancers were included in this study. Results. In 16 cases (28%), the histological grade of the metastatic lesion increased. This difference was statistically significant (P = 0.0232). In 16 cases (28%), the expression of p53 increased in the metastatic lesions, in 5 pairs from negative to positive, whereas the case decrease in the metastatic lesions was only 1. This difference was statistically significant (P = 0.0046). There was no significant difference in Ki-67 labeling indices and expression of CD44v6 between the primary and matched metastatic lesions. The degree of p53 expression in the metastatic lesions significantly correlated with disease-free survival (P = 0.0482), whereas that in the primary lesions did not. Moreover, high p53 expression in the metastatic lesions significantly correlated with disease-free survival in multivariate analysis. Conclusions. The p53 expression in metastatic lesions may reflect an aggressive biologic behavior in ovarian cancer.
UR - http://www.scopus.com/inward/record.url?scp=0032980607&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032980607&partnerID=8YFLogxK
U2 - 10.1006/gyno.1998.5266
DO - 10.1006/gyno.1998.5266
M3 - Article
C2 - 10053108
AN - SCOPUS:0032980607
VL - 72
SP - 360
EP - 366
JO - Gynecologic Oncology
JF - Gynecologic Oncology
SN - 0090-8258
IS - 3
ER -